Usefulness of applying lidocaine in esophagogastroduodenoscopy performed under sedation with propofol

Table 1 Comparison of basal characteristics of patients randomly assigned to the lidocaine and placebo treatment groups

	Lidocaine	Placebo	Diff1	P2
n	59	60
Age, yr	49.7 ± 15.81	51.7 ± 14.9	-2.0 (-7.6, 3.5)	0.47
Male sex	51.10%	48.60%	1.10%	0.85
	(37.0-65.0)	(37.6-51.8)	(0.5-2.3)
Weight, kg	70.8 ± 14.0	76.6 ± 17.0	-5.8 (-0.1, -11.4)	0.04
Height, cm	162.1 ± 9.0	162.2 ± 11.0	0.10 (-3.6, 3.7)	0.50
ASA  I-II	50.4 (40.5-60.5)	46.1 (28.7-64.5)	1.10 (0.7-1.7)	0.60
Mallampati I-II	51 (41.2-60.7)	48.9 (24.4-66.5)	0.84 (0.5-1.4)	0.49
Drug abuse	50 (26.3-76.3)	49.5 (40.3-58.7)	1.00 (0.5-1.9)	1.00
Previous sedated EGD	47.6 (28.3-67.6)	50 (40.2-59.7)	0.95 (0.6-1.5)	0.80

¹Differences are expressed as RR with their respective CIs or absolute values; ²Values in bold are statistically significant. Quantitative and qualitative variables are expressed as average ± SD and as percentage with 95%CI, respectively. EGD: Esophagogastroduodenoscop.